All In Biotech

Drug Trial Radar · NCT05813847

Herniorrhaphy for Postoperative Pain

A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of CPL-01 in the Management of Postoperative Pain After Open Inguinal Herniorrhaphy

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 518 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

518

Actual

Start

Apr 18, 2023

Primary completion

Sep 15, 2025

Study completion Oct 6, 2025

Sponsor

Lead sponsor
Cali Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Apr 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Subjects receive either CPL-01, positive control, or negative control after herniorrhaphy and are then followed.

Conditions

  • Hernia, Inguinal
  • Post Operative Pain

Interventions

  • local anaesthetic injection of CPL-01Drug

    Local infiltration of study drug

  • Morphine (rescue medication)Drug

    Opioid rescue allowed by IV if requested

  • Acetaminophen (rescue medication)Drug

    Acetaminophen rescue allowed if requested

  • Oxycodone (rescue medication)Drug

    Opioid rescue allowed by mouth if requested

  • local anaesthetic injection of placeboDrug

    Local infiltration of study drug

  • local anaesthetic injection of ropivacaine HClDrug

    Local infiltration of study drug

  • Open inguinal hernia repairProcedure

    Surgical hernia repair

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain controlTime frame: 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Todd Bertoch

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.